News und Analysen

Drug companies Merck (NYSE: MRK) and AbbVie (NYSE: ABBV) have been two of the best pharmaceutical investments, easily delivering better total returns than the S&P 500 average over the past three

Temperatures are rising. And so are concerns about what's next for the stock market. The answer to the former issue is air conditioning and/or a cool swim. The latter is more challenging.

However

Vertex Pharmaceuticals (NASDAQ: VRTX) is heading toward a big moment: a regulatory decision on what may become its next game-changing product. And this potential product, exa-cel for blood

Epcoritamab, a cancer drug co-developed by AbbVie (NYSE: ABBV) and Genmab (NASDAQ: GMAB), was recently given the green light by the Food and Drug Administration to be used as a treatment for adults

Shares in Pfizer (NYSE: PFE) were falling recently after it discontinued clinical trials for a potential diabetes and weight-loss therapy. The drop was due to negative perceptions after lotiglipron

On June 26, Pfizer (NYSE: PFE) gave investors an update that they probably didn't like. One of its two candidates for treating diabetes and obesity, called lotiglipron, will not be developed any

Shares of biosimilar pharmaceutical maker Alvotech (NASDAQ: ALVO) were up more than 11% as of noon on Friday. On Thursday, it plunged more than 6% after the company announced it had received a

Things have not quite gone as hoped lately for shares of Sarepta Therapeutics (NASDAQ: SRPT). Recently, the biotech received approval from the Food and Drug Administration (FDA) for its cutting-edge

Shares of Opko Health (NASDAQ: OPK) were up more than 11% around 2:30 p.m. ET on Thursday. The healthcare company announced after the markets closed on Wednesday that a treatment for pediatric

Biotech heavyweight Amgen (NASDAQ: AMGN) will probably continue to be an active player in the merger and acquisition (M&A) scene, regardless of what happens with its proposed $28 billion buyout of

If you're in search of bargain stocks to buy, the healthcare industry is a great place to start looking. The tech sector has been attracting more attention of late due to the hype around artificial

Artificial intelligence (AI) is an umbrella term for the use of computer vision, machine learning, and natural language processing to empower machines to do things that usually require human

There's nothing wrong with owning index funds, but growth stocks by definition outpace the revenue or profit of a typical stock, which likely results in greater gains than index funds can produce.

Whether you're saving for retirement, want to set aside money for travel, or just want to give yourself a raise, dividend stocks can help give you some extra income to accomplish those goals. Plus

Late last year, Open AI's ChatGPT introduced the wider world to the immense power of artificial intelligence (AI). However, pharmaceutical companies have been experimenting with various forms of

Shares of Orchestra BioMed Holdings (NASDAQ: OBIO) were up more than 16% as of 1:30 p.m. on Wednesday, as investors piled in on what looked like a bargain after the healthcare stock hit a low the

AbbVie (NYSE: ABBV) is facing a tough year ahead. The company's blockbuster drug Humira, which treats various autoimmune conditions such as rheumatoid arthritis, psoriasis, and Crohn's disease, will

Shares of Structure Therapeutics (NASDAQ: GPCR) closed up 18.35% on Monday after the clinical-stage biotech received what is perceived to be good news from Pfizer and a boost from an analyst. The

Amgen (NASDAQ: AMGN) stock came under renewed pressure on Monday, several days after more regulators piled on to block a major acquisition announced by the company. The immediate catalyst was a

Pfizer (NYSE: PFE) is having a rough session in early trading Monday. Specifically, the drugmaker's shares were down by 5.5% on heavy volume as of 10:24 a.m. ET Monday morning. 

The big dip came

Dividend-paying pharmaceutical stocks have an outstanding track record of producing market-beating returns on capital. The core reason is that major drug manufacturers tend to generate enormous free

Sometimes, a company hits a stumbling block -- or several of them. The stock plummets, and investors lose faith. But, in some cases, these down-on-their luck companies are able to turn things

What's the biggest knock against many high-yield dividend stocks? Probably that either the dividend or the share price is likely to sink sooner or later. That means that you often won't want to own

Shares of CureVac (NASDAQ: CVAC) were up by 14.3% for the week as of Friday morning, after having been up by as much as 16%, according to data provided by S&P Global Market Intelligence. The

Shares of Surmodics (NASDAQ: SRDX) were up by 24.1% for the week as of Friday morning, according to data provided by S&P Global Market Intelligence. The medical device company's stock closed last